A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.
Also called NCT07584967
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 400 participants
- Sponsor
- AnaCardio AB
- Registry
-
NCT07584967 -
2025-524469-25-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Bulgaria, Canada, Czechia, Poland, Slovakia, Spain, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT07584967. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-15 (anticipated); primary completion 2028-07-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
- Acronym
- GOAL-HF2
- Intervention (Drug)
- AC01
- Intervention (Other)
- Placebo
- Lead sponsor
- AnaCardio AB
Record details
- Record id
cardio:ct-nct07584967- Content hash
02928d8c5498c52892116f6057fd24960501f3195657108eca0ab45ae1ea39fa